{"pmid":32400931,"title":"Viral Shedding Prolongation in a Kidney Transplant Patient with COVID-19 Pneumonia.","text":["Viral Shedding Prolongation in a Kidney Transplant Patient with COVID-19 Pneumonia.","Coronavirus disease 2019 (COVID-19) pandemic sweeps the globe. The information regarding the kinetic changes of SARS-CoV-2 in immunosuppressed patients is unclear. Herein, we present a case of prolonged viral shedding in a transplant patient with COVID-19 pneumonia. A 49-year-old male kidney recipient was admitted to the hospital on February 7, 2020, for fever and fatigue. He was a permanent resident in Wuhan, China, and began having symptoms on January 29 (day 1 of illness). His maintenance immunosuppressive regime was consisted of tacrolimus (TAC, 1mg twice a day, orally), mycophenolate mofetil (MMF, 0.5g twice a day, orally) and prednisone (Pred, 5mg daily, orally) triple combination.","Am J Transplant","Zhang, Man","Zhang, Jing","Shi, Huibo","Liu, Bin","Zeng, Fanjun","32400931"],"abstract":["Coronavirus disease 2019 (COVID-19) pandemic sweeps the globe. The information regarding the kinetic changes of SARS-CoV-2 in immunosuppressed patients is unclear. Herein, we present a case of prolonged viral shedding in a transplant patient with COVID-19 pneumonia. A 49-year-old male kidney recipient was admitted to the hospital on February 7, 2020, for fever and fatigue. He was a permanent resident in Wuhan, China, and began having symptoms on January 29 (day 1 of illness). His maintenance immunosuppressive regime was consisted of tacrolimus (TAC, 1mg twice a day, orally), mycophenolate mofetil (MMF, 0.5g twice a day, orally) and prednisone (Pred, 5mg daily, orally) triple combination."],"journal":"Am J Transplant","authors":["Zhang, Man","Zhang, Jing","Shi, Huibo","Liu, Bin","Zeng, Fanjun"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400931","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ajt.15996","locations":["Wuhan","China","Pneumonia"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Tacrolimus","Prednisone","Mycophenolic Acid"],"topics":["Case Report"],"weight":1,"_version_":1666865855045042178,"score":9.490897,"similar":[{"pmid":32351040,"title":"COVID-19 in kidney transplant recipients.","text":["COVID-19 in kidney transplant recipients.","There is minimal information on COVID-19 in immunocompromised individuals. We have studied 10 patients treated at 12 adult care hospitals. Ten kidney transplant recipients tested positive for SARS-CoV-2 by PCR, and 9 were admitted. The median age was 57 (IQR 47-67), 60% were male, 40% Caucasian, and 30% Black/African American. Median time from transplant to COVID-19 testing was 2822 days (IQR 1272-4592). The most common symptom was fever, followed by cough, myalgia, chills, and fatigue. The most common CXR and CT abnormality was multifocal patchy opacities. 3 patients had no abnormal findings. Leukopenia was seen in 20% of patients, and allograft function was stable in 50% of patients. 9 patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. Hospitalized patients had their antimetabolite agent stopped. All hospitalized patients received hydroxychloroquine (HCQ) and azithromycin. 3 patients died (30%), five (50%) developed acute kidney injury. Kidney transplant recipients infected with COVID-19 should be monitored closely in the setting of lowered immunosuppression. Most individuals required hospitalization and presenting symptoms were similar to those of non-transplant individuals.","Am J Transplant","Nair, Vinay","Jandovitz, Nicholas","Hirsch, Jamie S","Nair, Gayatri","Abate, Mersema","Bhaskaran, Madhu","Grodstein, Elliot","Berlinrut, Ilan","Hirschwerk, David","Cohen, Stuart L","Davidson, Karina W","Dominello, Andrew J","Osorio, Gabrielle A","Richardson, Safiya","Teperman, Lewis W","Molmenti, Ernesto P","32351040"],"abstract":["There is minimal information on COVID-19 in immunocompromised individuals. We have studied 10 patients treated at 12 adult care hospitals. Ten kidney transplant recipients tested positive for SARS-CoV-2 by PCR, and 9 were admitted. The median age was 57 (IQR 47-67), 60% were male, 40% Caucasian, and 30% Black/African American. Median time from transplant to COVID-19 testing was 2822 days (IQR 1272-4592). The most common symptom was fever, followed by cough, myalgia, chills, and fatigue. The most common CXR and CT abnormality was multifocal patchy opacities. 3 patients had no abnormal findings. Leukopenia was seen in 20% of patients, and allograft function was stable in 50% of patients. 9 patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. Hospitalized patients had their antimetabolite agent stopped. All hospitalized patients received hydroxychloroquine (HCQ) and azithromycin. 3 patients died (30%), five (50%) developed acute kidney injury. Kidney transplant recipients infected with COVID-19 should be monitored closely in the setting of lowered immunosuppression. Most individuals required hospitalization and presenting symptoms were similar to those of non-transplant individuals."],"journal":"Am J Transplant","authors":["Nair, Vinay","Jandovitz, Nicholas","Hirsch, Jamie S","Nair, Gayatri","Abate, Mersema","Bhaskaran, Madhu","Grodstein, Elliot","Berlinrut, Ilan","Hirschwerk, David","Cohen, Stuart L","Davidson, Karina W","Dominello, Andrew J","Osorio, Gabrielle A","Richardson, Safiya","Teperman, Lewis W","Molmenti, Ernesto P"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32351040","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15967","locations":["Caucasian","myalgia","Leukopenia"],"e_drugs":["Tacrolimus","Azithromycin","Hydroxychloroquine","Prednisone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495707512832,"score":237.17792},{"pmid":32249089,"title":"Identification of Kidney Transplant Recipients with Coronavirus Disease 2019.","text":["Identification of Kidney Transplant Recipients with Coronavirus Disease 2019.","Coronavirus disease 2019 (COVID-19) is a novel and lethal infectious disease, posing a threat to global health security. The number of cases has increased rapidly, but no data concerning kidney transplant (KTx) recipients infected with COVID-19 are available. To present the epidemiological, clinical, and therapeutic characteristics of KTx recipients infected with COVID-19, we report on a case series of five patients who were confirmed as having COVID-19 through nucleic acid testing (NAT) from January 1, 2020 to February 28, 2020. The most common symptoms on admission to hospital were fever (five patients, 100%), cough (five patients, 100%), myalgia or fatigue (three patients, 60%), and sputum production (three patients, 60%); serum creatinine or urea nitrogen levels were slightly higher than those before symptom onset. Four patients received a reduced dose of maintenance immunosuppressive therapy during hospitalization. As of March 4, 2020 NAT was negative for COVID-19 in three patients twice in succession, and their computed tomography scans showed improved images. Although greater patient numbers and long-term follow-up data are needed, our series demonstrates that mild COVID-19 infection in KTx recipients can be managed using symptomatic support therapy combined with adjusted maintenance immunosuppressive therapy.","Eur Urol","Zhang, Hui","Chen, Yan","Yuan, Quan","Xia, Qiu-Xiang","Zeng, Xian-Peng","Peng, Jing-Tao","Liu, Jing","Xiao, Xing-Yuan","Jiang, Guo-Song","Xiao, Han-Yu","Xie, Liang-Bo","Chen, Jing","Liu, Jia-Li","Xiao, Xiong","Su, Hua","Zhang, Chun","Zhang, Xiao-Ping","Yang, Hua","Li, Heng","Wang, Zhen-Di","32249089"],"abstract":["Coronavirus disease 2019 (COVID-19) is a novel and lethal infectious disease, posing a threat to global health security. The number of cases has increased rapidly, but no data concerning kidney transplant (KTx) recipients infected with COVID-19 are available. To present the epidemiological, clinical, and therapeutic characteristics of KTx recipients infected with COVID-19, we report on a case series of five patients who were confirmed as having COVID-19 through nucleic acid testing (NAT) from January 1, 2020 to February 28, 2020. The most common symptoms on admission to hospital were fever (five patients, 100%), cough (five patients, 100%), myalgia or fatigue (three patients, 60%), and sputum production (three patients, 60%); serum creatinine or urea nitrogen levels were slightly higher than those before symptom onset. Four patients received a reduced dose of maintenance immunosuppressive therapy during hospitalization. As of March 4, 2020 NAT was negative for COVID-19 in three patients twice in succession, and their computed tomography scans showed improved images. Although greater patient numbers and long-term follow-up data are needed, our series demonstrates that mild COVID-19 infection in KTx recipients can be managed using symptomatic support therapy combined with adjusted maintenance immunosuppressive therapy."],"journal":"Eur Urol","authors":["Zhang, Hui","Chen, Yan","Yuan, Quan","Xia, Qiu-Xiang","Zeng, Xian-Peng","Peng, Jing-Tao","Liu, Jing","Xiao, Xing-Yuan","Jiang, Guo-Song","Xiao, Han-Yu","Xie, Liang-Bo","Chen, Jing","Liu, Jia-Li","Xiao, Xiong","Su, Hua","Zhang, Chun","Zhang, Xiao-Ping","Yang, Hua","Li, Heng","Wang, Zhen-Di"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32249089","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.eururo.2020.03.030","keywords":["clinical feature","coronavirus disease 2019","kidney transplant recipient"],"locations":["myalgia","fatigue"],"e_drugs":["Nitrogen","Creatinine","Urea"],"topics":["Case Report"],"weight":1,"_version_":1666138490967949312,"score":210.38249},{"pmid":32279418,"title":"Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19).","text":["Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19).","During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after two days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case-report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy.","Transpl Infect Dis","Bartiromo, Marilu","Borchi, Beatrice","Botta, Annarita","Bagala, Alfredo","Lugli, Gianmarco","Tilli, Marta","Cavallo, Annalisa","Xhaferi, Brunilda","Cutruzzula, Roberta","Vaglio, Augusto","Bresci, Silvia","Larti, Aida","Bartoloni, Alessandro","Cirami, Calogero","32279418"],"abstract":["During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after two days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case-report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy."],"journal":"Transpl Infect Dis","authors":["Bartiromo, Marilu","Borchi, Beatrice","Botta, Annarita","Bagala, Alfredo","Lugli, Gianmarco","Tilli, Marta","Cavallo, Annalisa","Xhaferi, Brunilda","Cutruzzula, Roberta","Vaglio, Augusto","Bresci, Silvia","Larti, Aida","Bartoloni, Alessandro","Cirami, Calogero"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32279418","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/tid.13286","keywords":["covid-19","drug-drug interaction","kidney transplant"],"e_drugs":["Hydroxychloroquine","Steroids","lopinavir-ritonavir drug combination","Tacrolimus"],"topics":["Case Report"],"weight":1,"_version_":1666138491570880516,"score":190.37466},{"pmid":32400074,"title":"COVID-19 pneumonia in lung transplant recipients: report of two cases.","text":["COVID-19 pneumonia in lung transplant recipients: report of two cases.","Coronavirus disease 2019 (COVID-19) has been declared pandemic since March 2020. In Europe, Italy has been the first nation affected by this infection. In this paper we report anamnestic data, clinical features and therapeutic management of two lung transplant recipients with confirmed COVID-19 pneumonia. Both patients were in good clinical conditions prior to the infection and were on immunosuppression with calcineurin inhibitors (CNI), mycophenolate mofetil and corticosteroids. Whilst mycophenolate mofetil was withdrawn in both cases, CNI were suspended only in the second patient. The first patient always maintained excellent oxygen saturation throughout hospitalization with no need for additional oxygen therapy. He was discharged with a satisfactory pulmonary function and a complete resolution of radiological and clinical findings. However, at discharge SARS-CoV-2 RNA could still be detected in the nasopharyngeal swab and in the stools. The second patient required mechanical ventilation, had a progressive deterioration of his clinical conditions and had a fatal outcome. Further insight into SARS-CoV-2 infection is eagerly awaited to improve the outcome transplant recipients affected by COVID-19 pneumonia.","Am J Transplant","Cozzi, Emanuele","Faccioli, Eleonora","Marinello, Serena","Loy, Monica","Congedi, Sabrina","Calabrese, Fiorella","Romagnoli, Micaela","Cattelan, Anna Maria","Rea, Federico","32400074"],"abstract":["Coronavirus disease 2019 (COVID-19) has been declared pandemic since March 2020. In Europe, Italy has been the first nation affected by this infection. In this paper we report anamnestic data, clinical features and therapeutic management of two lung transplant recipients with confirmed COVID-19 pneumonia. Both patients were in good clinical conditions prior to the infection and were on immunosuppression with calcineurin inhibitors (CNI), mycophenolate mofetil and corticosteroids. Whilst mycophenolate mofetil was withdrawn in both cases, CNI were suspended only in the second patient. The first patient always maintained excellent oxygen saturation throughout hospitalization with no need for additional oxygen therapy. He was discharged with a satisfactory pulmonary function and a complete resolution of radiological and clinical findings. However, at discharge SARS-CoV-2 RNA could still be detected in the nasopharyngeal swab and in the stools. The second patient required mechanical ventilation, had a progressive deterioration of his clinical conditions and had a fatal outcome. Further insight into SARS-CoV-2 infection is eagerly awaited to improve the outcome transplant recipients affected by COVID-19 pneumonia."],"journal":"Am J Transplant","authors":["Cozzi, Emanuele","Faccioli, Eleonora","Marinello, Serena","Loy, Monica","Congedi, Sabrina","Calabrese, Fiorella","Romagnoli, Micaela","Cattelan, Anna Maria","Rea, Federico"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400074","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ajt.15993","locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["Mycophenolic Acid"],"topics":["Case Report"],"weight":1,"_version_":1666865855061819392,"score":187.28221},{"pmid":32471001,"title":"COVID-19 in elderly kidney transplant recipients.","text":["COVID-19 in elderly kidney transplant recipients.","The SARS-Cov-2 infection disease (COVID-19) pandemic has posed at risk the kidney transplant (KT) population, particularly the elderly recipients. From March-12(th) until April-4(th) 2020, we diagnosed COVID-19 in 16 of our 324 KT patients aged >/=65 years old (4.9%). Many of them had had contact with healthcare facilities in the month prior to infection. Median time of symptom onset to admission was 7 days. All presented with fever and all but one with pneumonia. Up to 33% showed renal graft dysfunction. At infection diagnosis, mTOR inhibitors or mycophenolate were withdrawn. Tacrolimus was withdrawn in 70%. The main treatment combination was hydroxychloroquine and azithromycin. A subset of patients was treated with anti-retroviral and tocilizumab. Short-term fatality rate was 50% at a median time since admission of 3 days. Those who died were more frequently obese, frail and had underlying heart disease. Although a higher respiratory rate was observed at admission in nonsurvivors, symptoms at presentation were similar between both groups. Patients who died were more anemic, lymphopenic and showed higher D-dimer, C-reactive protein, and IL-6 at their first tests. COVID-19 is frequent among the elderly KT population and associates a very early and high mortality rate.","Am J Transplant","Crespo, Marta","Jose Perez-Saez, Maria","Redondo-Pachon, Dolores","Llinas-Mallol, Laura","Montero, Maria Milagro","Villar, Judith","Arias-Cabrales, Carlos","Buxeda, Anna","Burballa, Carla","Vazquez, Susana","Lopez, Thais","Moreno, Fatima","Mir, Marisa","Outon, Sara","Sierra, Adriana","Collado, Silvia","Barrios, Clara","Rodriguez, Eva","Sans, Laia","Barbosa, Francesc","Cao, Higini","Arenas, Maria Dolores","Guerri-Fernandez, Roberto","Horcajada, Juan Pablo","Pascual, Julio","32471001"],"abstract":["The SARS-Cov-2 infection disease (COVID-19) pandemic has posed at risk the kidney transplant (KT) population, particularly the elderly recipients. From March-12(th) until April-4(th) 2020, we diagnosed COVID-19 in 16 of our 324 KT patients aged >/=65 years old (4.9%). Many of them had had contact with healthcare facilities in the month prior to infection. Median time of symptom onset to admission was 7 days. All presented with fever and all but one with pneumonia. Up to 33% showed renal graft dysfunction. At infection diagnosis, mTOR inhibitors or mycophenolate were withdrawn. Tacrolimus was withdrawn in 70%. The main treatment combination was hydroxychloroquine and azithromycin. A subset of patients was treated with anti-retroviral and tocilizumab. Short-term fatality rate was 50% at a median time since admission of 3 days. Those who died were more frequently obese, frail and had underlying heart disease. Although a higher respiratory rate was observed at admission in nonsurvivors, symptoms at presentation were similar between both groups. Patients who died were more anemic, lymphopenic and showed higher D-dimer, C-reactive protein, and IL-6 at their first tests. COVID-19 is frequent among the elderly KT population and associates a very early and high mortality rate."],"journal":"Am J Transplant","authors":["Crespo, Marta","Jose Perez-Saez, Maria","Redondo-Pachon, Dolores","Llinas-Mallol, Laura","Montero, Maria Milagro","Villar, Judith","Arias-Cabrales, Carlos","Buxeda, Anna","Burballa, Carla","Vazquez, Susana","Lopez, Thais","Moreno, Fatima","Mir, Marisa","Outon, Sara","Sierra, Adriana","Collado, Silvia","Barrios, Clara","Rodriguez, Eva","Sans, Laia","Barbosa, Francesc","Cao, Higini","Arenas, Maria Dolores","Guerri-Fernandez, Roberto","Horcajada, Juan Pablo","Pascual, Julio"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32471001","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/ajt.16096","locations":["obese"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668167109982552064,"score":168.27423}]}